Sign In
New User? Register Here
News | Stents | June 04, 2024
The non-surgical device prevents dangerous plaque buildup in neck arteries from cutting off oxygen to the brain
June 4, 2024 — A patient at HonorHealth Research Institute is one of the nation’s first — and the first in Arizona and the Southwest — to undergo a non-surgical, catheter-based procedure with a new type of stroke-prevention stent that eliminates blockages in neck arteries that could potentially cause a deadly stoke by depriving the brain of oxygen.
TheNeuroguard Integrated Embolic Protection (IEP)system is an experimental treatment for carotid artery stenosis, also known as carotid artery disease, a condition in which fatty-waxy deposits known as plaque builds up and blocks the normal flow of blood in the large arteries on either side of the neck. Left untreated, this condition can lead to stroke with severe complications, which could include death.
The physician who performed the procedure,Venkatesh Ramaiah, M.D., a vascular surgeon and director of HonorHealth’s vascular services, said the device avoids carotid endarterectomy, a previous method for removing plaque from carotid arteries, which involves a surgical procedure requiring an incision directly into the neck.
“This new system combines a truly innovative stent design,” said Dr. Ramaiah, a former director of the Arizona Heart Hospital. “We were fortunate to be the first in the Southwest to use such technology.”
Designed by Raleigh, N.C.-based Contego Medical Inc., theNeuroguard IEP3-in-1 carotid stent and post-dilation balloon system is designed to deliver a self-expanding carotid artery stent while using a special filter to prevent emboli (blockage) debris from reaching the brain. The stent is made of nitinol, a superelastic nickel-titanium metal alloy that is ideal for creating flexible endoscopic devices that can navigate narrow areas in the body and transform into a rigid shape when needed.
The first patient to undergo the procedure as part of the Research Institute’s Performance III clinical trial is Roslyn “Sunny” Gomes of Glendale, Ariz., who has suffered from peripheral artery disease for years. She already has three stents in her heart and so many stents and replacement arteries in both her legs that she’s lost count.
A previous scan some years ago had shown a partial blockage of her right carotid artery, but a recent set of scans showed it was 85% blocked, making her a good candidate for the new clinical trial.
“I feel a lot better today than I have,” said Sunny, 76, days after her procedure. “I really love Dr. Ramaiah. He’s been really good to me. He’s saved my right leg twice now.”
HonorHealth Research Institute is one of 30 sites worldwide to offer the device. Patients are monitored for 6 months. Enrollment in the clinical trial is expected to continue through the end of 2024.
For more information:www.honorhealth.com
Related Content
News | Balloon Catheter
FDA Announces Medos International Sàrl Recall of Cerenovus CEREBASE DA Guide Sheath due to Cracking of the Distal Catheter Shaft
April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...
April 04, 2024
News | Balloon Catheter
Injectable Angioplasty Balloon Catheter Transforms Peripheral Procedures, Users Report Reduced Equipment and Contrast Needs
January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...
January 18, 2024
News | Balloon Catheter
Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex Scoring Balloon
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
February 25, 2022
News | Balloon Catheter
CERENOVUS Launches EMBOGUARD Balloon Guide Catheter to Use In the Treatment of Acute Ischemic Stroke
February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...
February 15, 2022
News | Balloon Catheter
Boston Scientific Initiates First Coronary Drug-Coated Balloon Study in the U.S.
May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...
May 20, 2021
Feature | Balloon Catheter | By Dave Fornell, Editor
Overview of Angioplasty Balloon Technology Advances
The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...
March 16, 2021
Feature | Balloon Catheter
FDA Clears Coronary Intravascular Lithotripsy to Breakup Calcified Lesions With Sound Waves
February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...
February 17, 2021
News | Balloon Catheter
FDA Clears Scoring Sheath That Fits Over Standard Angioplasty Balloons
June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...
June 04, 2020
News | Balloon Catheter
Abbott Recalls Two Coronary Balloon Catheters That May Not Deflate
February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...
February 24, 2020
News | Balloon Catheter
Edwards Lifesciences Recalls IntraClude Intra-aortic Occlusion Device
July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...
July 15, 2019
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now